A randomized controlled trial found that adding 75g IV vitamin C to chemotherapy doubled median survival compared with chemotherapy alone — in one of the deadliest cancers known.
by Nicolas Hulscher, MPH
Before we dig into the extremely promising randomized trial, it’s important to understand that over 100 studies and decades of evidence reveal
that vitamin C exerts anti-cancer effects through four powerful
mechanisms: pro-oxidative cytotoxicity, epigenetic reprogramming,
signaling-pathway suppression, and immune activation. A recent
comprehensive review paper titled, High-dose vitamin C: A promising anti-tumor agent, insight from mechanisms, clinical research, and challenges,
analyzed 150+ studies and found that when vitamin C reaches true
pharmacologic levels (20–30 mM), it behaves like a targeted,
tumor-selective therapy — something past trials missed by under-dosing.
Now, a recently published randomized controlled trialhas
reported striking results in one of the deadliest cancers: Stage IV
pancreatic ductal adenocarcinoma. Researchers tested whether adding
high-dose intravenous vitamin C (75 grams, 3 times per week) to standard
chemotherapy could improve survival outcomes.
Patients
were randomized 1:1 to receive either gemcitabine plus nab-paclitaxel
alone (n=16) or the same chemotherapy regimen combined with
pharmacologic IV vitamin C (75 g, three times weekly) (n=18).
The results were striking in patients with Stage IV pancreatic cancer who received high-dose IV vitamin C:
- Median overall survival doubled
8.3 months (chemo alone) → 16 months (chemo + IV vitamin C)
- ~54% reduction in risk of death
Hazard ratio: 0.46
- Progression-free survival improved
3.9 months → 6.2 months
- Higher objective response rate
23% → 38%
- Lower rates of serious adverse events overall
- Lower rates of severe hematologic toxicity (e.g., neutropenia)
- Pharmacologic plasma vitamin C levels achieved (~500-fold increase)
Both
groups received identical chemotherapy backbones, meaning the survival
difference is attributable to the addition of vitamin C.
While the
trial was relatively small and stopped early at interim analysis due to
a strong efficacy signal, the magnitude of effect in a randomized
setting is difficult to ignore. In a disease where median survival has
historically hovered around 8–11 months, doubling survival warrants
serious attention and larger confirmatory trials.
This study represents one of the strongest modern clinical signals supporting high-dose vitamin C as an anti-cancer agent.
Nicolas Hulscher, MPH
Epidemiologist and Foundation Administrator, McCullough Foundation
Support our mission: mcculloughfnd.org